<DOC>
	<DOCNO>NCT02107235</DOCNO>
	<brief_summary>The work hypothesis oral rigosertib treatment add platinum-based Chemoradiotherapy ( CRT ) improve progression-free survival first-line patient intermediate- high-risk human papillomavirus negative positive ( HPV ( + ) ) Head Neck Squamous Cell Carcinoma . This study determine high safe dose oral rigosertib use cisplatin CRT . This study also record side effect may occur measure tumor size long patient live .</brief_summary>
	<brief_title>Platinum-based Chemoradiotherapy Rigosertib Head Neck Cancer</brief_title>
	<detailed_description>This multicenter , dose-escalating study oral rigosertib administer concurrent cisplatin Radiotherapy patient intermediate- high-risk Head Neck Squamous Cell Carcinoma . Three rigosertib escalate cohort ( 6 patient per cohort ) sequentially evaluate : 70 mg 3 time day ( TID ) , 140 mg TID 280 mg TID . The total treatment course 8 week : 1 week oral rigosertib alone ( 70 mg TID , 140 mg TID 280 mg TID ) follow 7 week concurrent administration rigosertib , cisplatin radiation therapy . After completion treatment , patient follow 36 month document Progression-free Survival Overall Survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Pathologically confirm diagnosis Squamous Cell Carcinoma oropharynx ( tonsil , base tongue , soft palate , oropharyngeal wall ) , hypopharynx , larynx . 2 . Patient appropriate candidate definitive chemoradiotherapy . 3 . Intermediaterisk Head Neck Squamous Cell Carcinoma ( HNSCC ) , define follow : 1 . Clinical stage T24 , N2aN3 T34 , N0N3 2 . P16 ( + ) immunohistochemistry ( IHC ) HPV ( + ) situ hybridization ( ISH ) 3 . Smoking status ≥ 10 packyears , &lt; 10 packyears T4 N2cN3 . 4 . If intermediaterisk HNSCC , highrisk HNSCC , define follow : 1 . Clinical stage T24 , N2aN3 T34 , N0N3 . 2 . P16 ( ) IHC HPV ( ) ISH . 5 . No evidence distant metastasis . 6 . Clinically radiographically evident measurable disease ( defined RECIST v 1.1 ) primary site nodal station . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 8 . Adequate hematologic function define absolute neutrophil count ( ANC ) ≥ 1800/μL ; platelet ( PLT ) ≥ 100,000/μL ; Hgb ≥ 8.0 g/dL . 9 . Adequate renal function , define serum creatinine ≤ 1.5 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 60 mL/min . 10 . Adequate liver function define total bilirubin ≤ 1.5 x ULN ; aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 2.5 x ULN ; prothrombin time ≤ 1.5 x ULN , unless receive therapeutic anticoagulation . 11 . Ability understand nature study hazard study participation , communicate satisfactorily Investigator , follow requirement entire protocol . 12 . Willingness adhere prohibition restriction specify protocol . 13 . The patient must sign informed consent form ( ICF ) indicate s/he understands purpose procedure require study willing participate study . 1 . Gross total excision primary nodal disease . 2 . Prior treatment IV oral rigosertib . 3 . Prior chemotherapy study HNSCC cancer . 4 . Prior radiotherapy region study HNSCC cancer adjacent anatomical site , &gt; 25 % marrowbearing area . 5 . Synchronous malignancy . 6 . Prior invasive malignancy unless patient diseasefree minimum 3 year ; however , patient prior nonmelanoma skin cancer , cervical intraepithelial neoplasia ( CIN ) , prostate cancer undetectable prostatespecific antigen ( PSA ) may enrol . 7 . Severe , active comorbidity . 8 . Known infection human immunodeficiency virus ( HIV ) . 9 . Any uncontrolled condition , opinion Investigator , could affect subject 's participation study . 10 . Major surgery within 3 week enrollment major surgery without full recovery . 11 . Ascites require active medical management , include paracentesis . 12 . Hyponatremia ( define serum sodium &lt; 130 milliequivalent mEq/L ) condition may predispose patient hyponatremia . 13 . Uncontrolled hypertension , define systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mmHg , despite treatment 2 antihypertensive agent . 14 . New onset seizure within 3 month prior enrollment , poorly control seizure . 15 . Female patient pregnant lactate . 16 . Female patient childbearing potential male patient partner childbearing potential unwilling follow strict contraception requirement . 17 . Female patient childbearing potential negative blood urine pregnancy test Screening . 18 . History allergic reaction attribute compound similar chemical biologic composition rigosertib . 19 . Prior therapy phosphatidylinositol 3 kinase ( PI3K ) , Akt mammalian target rapamycin ( mTOR ) inhibitor . 20 . Any investigational agent chemotherapy , radiotherapy , immunotherapy within 4 week enrollment . 21 . Psychiatric illness/social situation would limit patient 's ability tolerate and/or comply study requirement , inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>cisplatin</keyword>
</DOC>